RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Among the movers:
Allied Healthcare Products (NASDAQ:AHPI) +106% to $32.10 -this was a $1 stock a couple of months back.
iBio (NYSEMKT:IBIO) +117%
Alpha Pro Tech (NYSEMKT:APT) +43%
Lakeland Industries (NASDAQ:LAKE) +35%
Vaxart (NASDAQ:VXRT) +44%
Co-Diagnostics (NASDAQ:CODX) +19%
novio Pharmaceuticals (NASDAQ:INO) +10%
Novavax (NASDAQ:NVAX) +30%
BioCryst Pharmaceuticals (NASDAQ:BCRX) +12%
Cocrystal Pharma (NASDAQ:COCP) +16%
Sanofi (NASDAQ:SNY) says it reached an $11.85M settlement agreement with the U.S. Department of Justice to resolve allegations that it used a charity that helps cover Medicare patients’ out-of-pocket drug costs as a way to pay them kickbacks to use a high-priced multiple sclerosis drug.
The deal is the latest to result from an industry-wide probe of drugmakers’ financial support of patient assistance charities that has resulted in more than $865M in settlements.
The DoJ says Sanofi provided payments to such a charity, The Assistance Fund, not for a charitable purpose but instead to use it as a means to cover the co-pay obligations of Medicare patients using the Lemtrada multiple sclerosis drug.
Sanofi does not admit wrongdoing as part of the settlement, and defends the practice of providing financial support to such charitable groups.
Pfizer (NYSE:PFE) has received FDA approval for its new combination drug Advil Dual Action, a pain reliever combining acetaminophen with Advil’s typical ibuprofen.
The two-medicine tablets each contain 250 mg of acetaminophen and 125 mg of ibuprofen.
Sorrento Therapeutics (NASDAQ:SRNE) announces that an interim analysis of an ongoing Phase 1b study of resiniferatoxin (RTX) administered via epidural route in patients with intractable cancer pain has generated positive data.
Data is available from 14 subjects with advanced cancer pain who received a single epidural injection of RTX from 0.4 to 15 ug.
No dose limiting toxicities were encountered. The most common treatment-related adverse event was transient post-procedural pain: 7 of 14 subjects (50%) reported moderate severity.
The ongoing trial will follow subjects for at least 84 days. The lower doses did not demonstrate notable pain relief, but permitted dose escalation.
Three subjects at the higher doses had rapid and marked pain reduction after treatment.
One additional cohort was added to further evaluate a 25 ug dose for upcoming Phase 3 studies.
Detailed results of the completed study are expected later this year.
Shares are up 1% premarket.
Cepheid (NYSE:DHR) and Sherlock Biosciences announce a research collaboration between the two companies to explore the development of new cutting-edge molecular diagnostic tests.
The companies plan to leverage Sherlock Biosciences’ engineering biology platform to identify genetic targets and run new tests on Cepheid’s GeneXpert Systems.
The collaboration will focus on molecular diagnostic tests for infectious diseases and oncology, beginning with a proof-of-concept project focused on detection of coronavirus (SARS-CoV-2).
